Canada Spends Logo

Explore our Budget 2026 analysis

Grant: KRESCENT / CIHR New Investigators

McMaster University

$26,250.00

The Association of Beta Blocker use with Mortality in Patients with Heart Failure and Severe Chronic Kidney Disease

FY 2015-16

Summary
Chronic kidney disease (CKD) affects 18.6% (4.4 million) of the adult Canadian population age 65 years and older. Patients with chronic kidney disease (CKD) are at increased risk of developing heart failure. Patients who have both chronic kidney disease and heart failure have a high risk of death. A medication that slows down the heart rate, called a beta-blocker, is known to reduce death in patients with heart failure who do not have significant kidney disease. Unfortunately, it remains unknown if beta-blockers reduce death in patients with both severe CKD and heart failure. Uncertainty with respect to the overall risks and benefits of betablockers is likely a major reason for their underuse in patients with both CKD and heart failure. More information on the benefits of beta-blockers in patients with CKD and heart failure is needed. If beta-blockers do in fact reduce death in patients with heart failure and CKD, then many patients are missing out on a potentially life saving therapy. To better determine the effects of beta-blockers in older individuals with kidney disease and heart failure, we will study several thousands of patients across the province of Ontario using a large already established database. We will examine whether or not beta-blockers reduce the risk of death, kidney failure and hospital admissions with heart failure for older individuals with advanced chronic kidney disease and heart failure. Our study will ultimately lead to a better understanding of how to care for a large subset of the chronic kidney disease population.
Program
KRESCENT / CIHR New Investigators
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
350628
Name
Molnar Amber
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Kidney Foundation of Canada
Prcname2
Special Cases - Awards Programs
Projecttitle
The Association of Beta Blocker use with Mortality in Patients with Heart Failure and Severe Chronic Kidney Disease
Programtype2
Salary Programs
Orgnameinp2
McMaster University
Cihramount2
$26,250
Cihrequipment2
$0
Programname2
KRESCENT / CIHR New Investigators
Keyworddelim
Beta-Blockers; Chronic Kidney Disease; Congestive Heart Failure; Mortality; Observational Study
Abstract
Chronic kidney disease (CKD) affects 18.6% (4.4 million) of the adult Canadian population age 65 years and older. Patients with chronic kidney disease (CKD) are at increased risk of developing heart failure. Patients who have both chronic kidney disease and heart failure have a high risk of death. A medication that slows down the heart rate, called a beta-blocker, is known to reduce death in patients with heart failure who do not have significant kidney disease. Unfortunately, it remains unknown if beta-blockers reduce death in patients with both severe CKD and heart failure. Uncertainty with respect to the overall risks and benefits of betablockers is likely a major reason for their underuse in patients with both CKD and heart failure. More information on the benefits of beta-blockers in patients with CKD and heart failure is needed. If beta-blockers do in fact reduce death in patients with heart failure and CKD, then many patients are missing out on a potentially life saving therapy. To better determine the effects of beta-blockers in older individuals with kidney disease and heart failure, we will study several thousands of patients across the province of Ontario using a large already established database. We will examine whether or not beta-blockers reduce the risk of death, kidney failure and hospital admissions with heart failure for older individuals with advanced chronic kidney disease and heart failure. Our study will ultimately lead to a better understanding of how to care for a large subset of the chronic kidney disease population.
Competitiondate
201602
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Molnar, Amber
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $26,250~ $0~